ID Lectures / Resident and fellow education

Acute tick-borne infections

Recognition, initial testing, empiric treatment, and reassessment, including tularemia.

Resident core / Optional fellow detail and clinical reference / Edited November 10, 2026

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

Resident core

Acute tick-borne illness

Fever with cytopenias, an inoculation ulcer or eschar, and fever with hemolysis suggest different diagnoses and specimen choices. The resident core covers the initial decisions. The reference sections compare organisms, tests, and treatment evidence.

Companion lecture: Lyme disease. Use it for an expanding erythema migrans-like rash, bite prophylaxis, carditis, arthritis, or persistent symptoms after treatment.

Resident core

Regional exposure in the United States

Explore by infection

Choose an infection to shade the map, or choose a location to see all associations recorded in this lecture. Location results are independent of the selected infection.

Map fits screen
AlabamaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingPuerto RicoPuerto Rico
Choose a location to see its mapped infection associations.

Colors are specific to the selected infection, not a universal risk scale. Whole-state or country shading does not imply uniform local transmission. The maps show selected associations, not an exhaustive differential.

Static regional map and print view
Map of the contiguous United States with six teaching regions: Northeast and mid-Atlantic, Midwest and Great Lakes, south-central, Southeast and Gulf or Atlantic, West and northern Plains, and Pacific Coast. RMSF labels emphasize south-central and southeastern exposure, and the map also notes southwestern foci. The table below lists the infections and exceptions.
Broad geographic teaching regions, not disease-risk boundaries. Shading does not mean uniform transmission throughout a state or country. Basemap: U.S. Census Bureau 2025 cartographic boundaries.

Rocky Mountain spotted fever is not confined to the Rocky Mountains. Consider RMSF after compatible exposure in the central and eastern U.S., including Missouri and the Southeast, as well as western regions. Arizona and northern Mexico have important brown-dog-tick-associated foci.

Surveillance distinction: CDC geographic totals combine RMSF with other spotted fever rickettsioses (SFR). The concentration of reported SFR in south-central and southeastern states should not be presented as a map of species-confirmed RMSF. Routine serology often cannot distinguish the species. CDC geographic and vector guidance.

RegionInfections to considerUseful distinction
Northeast / mid-AtlanticLyme, B. microti babesiosis, anaplasmosis, B. miyamotoi; PowassanShared Ixodes exposure does not mean equal incidence. Hemolysis suggests Babesia; encephalitis raises Powassan.
Midwest / Great LakesThe Ixodes-associated group, with higher incidence in the upper Midwest; E. muris eauclairensis especially Minnesota/WisconsinAsk about travel to Wisconsin/Minnesota even when the patient lives in Missouri.
South-central / MissouriRMSF and other spotted fevers, ehrlichiosis, tularemia, Heartland/Bourbon, STARI; rare locally acquired divergens-like/MO-1 babesiosis; soft-tick relapsing fever in parts of TexasMissouri is not Babesia-free. Anaplasmosis reports do not by themselves establish local acquisition; serologic cross-reactions occur. Lyme requires an exposure-specific assessment.
Southeast / Gulf / AtlanticRMSF, ehrlichiosis and other spotted fevers; R. parkeri along Gulf/Atlantic areas; Heartland/Bourbon; STARIRanges overlap the Northeast and south-central areas. Eschar plus fever favors an eschar-associated rickettsiosis over classic RMSF.
West / northern PlainsColorado tick fever; soft-tick relapsing fever; tularemia and RMSF also occurMountain hiking favors Colorado tick fever; rodent-infested cabins favor relapsing fever. Southwestern brown-dog-tick settings can have severe RMSF.
Pacific CoastFocal Lyme/anaplasmosis and B. miyamotoi; Pacific Coast tick fever in California; B. duncani in California/Washington; soft-tick relapsing fever; Colorado tick fever in Oregon mountain exposuresDo not apply Northeast incidence to the West Coast. Babesiosis is not exclusively B. microti, and transfusion exposure bypasses geography.

The U.S. map focuses on the contiguous states. The interactive view also has a Puerto Rico inset. Alaska and Hawaii are outside its scope. Geography changes pretest probability but cannot exclude infection. Ask where the exposure occurred, the habitat, season, animal contact, and transfusion history. Tick-range maps are not disease-incidence maps.

Lyme testing and treatment | International exposures | Viral testing pathways

Sources [34], [35], [36], [27].

Missouri babesiosis is documented, including locally acquired divergens-like/MO-1 infection. A negative B. microti-specific PCR does not exclude other Babesia species. For hemolysis with compatible illness, request manual smear review and confirm assay coverage with microbiology. Missouri case; Missouri diagnostic guidance.

Regional reference

International exposures

Explore by infection

Choose an infection to shade the map, or choose a location to see all associations recorded in this lecture. Location results are independent of the selected infection.

Map fits screen
FijiTanzaniaW. SaharaCanadaUnited States of AmericaKazakhstanUzbekistanPapua New GuineaIndonesiaArgentinaChileDem. Rep. CongoSomaliaKenyaSudanChadHaitiDominican Rep.RussiaBahamasFalkland Is.NorwayGreenlandFr. S. Antarctic LandsTimor-LesteSouth AfricaLesothoMexicoUruguayBrazilBoliviaPeruColombiaPanamaCosta RicaNicaraguaHondurasEl SalvadorGuatemalaBelizeVenezuelaGuyanaSurinameFranceFrench GuianaEcuadorPuerto RicoJamaicaCubaZimbabweBotswanaNamibiaSenegalMaliMauritaniaBeninNigerNigeriaCameroonTogoGhanaCôte d'IvoireGuineaGuinea-BissauLiberiaSierra LeoneBurkina FasoCentral African Rep.CongoGabonEq. GuineaZambiaMalawiMozambiqueeSwatiniAngolaBurundiIsraelLebanonMadagascarPalestineGambiaTunisiaAlgeriaJordanUnited Arab EmiratesQatarKuwaitIraqOmanVanuatuCambodiaThailandLaosMyanmarVietnamNorth KoreaSouth KoreaMongoliaIndiaBangladeshBhutanNepalPakistanAfghanistanTajikistanKyrgyzstanTurkmenistanIranSyriaArmeniaSwedenBelarusUkrainePolandAustriaHungaryMoldovaRomaniaLithuaniaLatviaEstoniaGermanyBulgariaGreeceTurkeyAlbaniaCroatiaSwitzerlandLuxembourgBelgiumNetherlandsPortugalSpainIrelandNew CaledoniaSolomon Is.New ZealandAustraliaSri LankaChinaTaiwanItalyDenmarkUnited KingdomIcelandAzerbaijanGeorgiaPhilippinesMalaysiaBruneiSloveniaFinlandSlovakiaCzechiaEritreaJapanParaguayYemenSaudi ArabiaAntarcticaN. CyprusCyprusMoroccoEgyptLibyaEthiopiaDjiboutiSomalilandUgandaRwandaBosnia and Herz.North MacedoniaSerbiaMontenegroKosovoTrinidad and TobagoS. Sudan
Choose a location to see its mapped infection associations.

Colors are specific to the selected infection, not a universal risk scale. Whole-state or country shading does not imply uniform local transmission. The maps show selected associations, not an exhaustive differential.

Static regional map and print view
World map of seven travel teaching regions: Mexico and Central and South America, sub-Saharan Africa and the Caribbean, Mediterranean and Middle East, Europe and northern Asia, East Asia, South and Southeast Asia, and Australia. The table below lists the infections and exceptions for each region.
Broad geographic teaching regions, not disease-risk boundaries. Shading does not mean uniform transmission throughout a state or country. Basemap: Natural Earth. French Guiana is shown separately from metropolitan France and remains unshaded in this regional view.
Travel regionSelected infectionsClinical implication
Mexico / Central and South AmericaR. rickettsii spotted fever, including Brazilian spotted fever; other spotted feversRMSF also occurs in North America, including the U.S. and Canada. Exposure is focal and country lists are incomplete; the disease name is not a range boundary.
Sub-Saharan Africa / CaribbeanR. africae African tick-bite fever, especially safari/game exposures and some Caribbean islandsMultiple eschars or affected travel companions are helpful clues. CCHF also occurs in parts of Africa, but is a separate exposure and severity assessment, not a Caribbean association.
Mediterranean / Middle EastR. conorii and related spotted fevers; CCHF in selected areas, including parts of southern/eastern EuropeFever, rash, eschar can be spotted fever. Compatible acute illness after a credible CCHF exposure warrants immediate isolation and notification of infection prevention and public health. Hemorrhage and severe thrombocytopenia are not prerequisites. CDC screening and isolation guidance.
Europe / northern AsiaLyme borreliosis; focal tick-borne encephalitis (TBE); tularemia in parts of the Northern HemisphereTBE risk varies markedly within countries. Ask about forest exposure and unpasteurized dairy. European Lyme also involves B. afzelii and B. garinii.
East AsiaSFTS, chiefly China, South Korea and Japan, with human evidence also in Taiwan and parts of Southeast Asia; regional spotted fevers and scrub typhusFever, GI illness, cytopenias or organ failure after rural/outdoor exposure. Animal blood/body-fluid contact also matters. TBE occurs in parts of the broader region.
South / Southeast AsiaRegional spotted fevers; CCHF in parts of South Asia; SFTS evidence in several Southeast Asian countries; scrub typhusScrub typhus is mite-borne, not tick-borne. Eschar may be absent. Consider malaria urgently after exposure in a malaria-endemic area.
AustraliaQueensland tick typhus and Flinders Island spotted feverQueensland tick typhus favors eastern/coastal exposure; Flinders Island spotted fever principally southern Australia. Scrub typhus is a distinct mite-borne differential in tropical/northern areas.

These are selected teaching associations, not an exhaustive world distribution atlas. CCHF spans parts of Africa, Europe, the Middle East, and Asia and crosses several shaded regions. Use destination-level data before advising a traveler or excluding a diagnosis. Other zoonoses require different maps and exposure histories.

Sources [37], [38], [29], [39], [40].

Beyond the U.S., Lyme borreliosis occurs in Canada, Europe and temperate Asia. Soft-tick relapsing fever has a much broader international distribution than the U.S. cabin-associated pattern. No single regional map is an exhaustive differential. ECDC Lyme geography; Canadian Lyme geography.

Additional regional sources: UKHSA CCHF/SFTS country evidence; CDC rickettsial geography; Queensland tick typhus; Flinders Island spotted fever.

Additional geographic exceptions for the print view: scrub typhus includes East Asia and northern Australia, with human Orientia infections also described in Chile and the UAE. SFTS human evidence extends to Taiwan, Thailand, Vietnam and Myanmar; Pakistan serology is a different level of evidence. CCHF extends beyond the Balkans and includes locally acquired cases in Spain and Portugal. Use the linked country guidance for dates and evidence categories.

Resident core

Start with the syndrome and the exposure

Admit or urgently escalate care for shock, hypoxemia, altered mental status, major organ dysfunction, or inability to take effective therapy. Clinical clues shift probability; no single absent rash, eschar, recalled bite, or early negative test rules out these infections. Surveillance case definitions are for reporting and should not delay bedside treatment.

Fever with a plausible exposure and severe headache, cytopenias, hepatitis, rash, or organ dysfunction can fit a rickettsial illness. CDC recommends prompt doxycycline when RMSF, ehrlichiosis, or anaplasmosis is suspected. An absent rash, an unrecognized bite, or negative acute testing should not delay effective treatment. Other indicated sepsis or meningitis coverage remains necessary during evaluation.
PatternPrioritizeImmediate distinction
Acute fever + low platelets + leukopenia + elevated aminotransferasesEhrlichiosis, anaplasmosis; Heartland/Bourbon virusHemolysis suggests Babesia. Normal counts early do not exclude rickettsial infection.
Fever + severe headache, evolving rash, hyponatremiaRMSFRash may be absent early or throughout illness. Delay in therapy can be fatal.
Ulcer or black eschar + regional lymphadenopathyTularemia; R. parkeri; travel-associated spotted feversExamine scalp, axillae, groin, and skin folds. An ulcer is not necessarily a necrotic eschar.
Expanding erythema, facial palsy, heart block, or large-joint effusionLyme diseaseLyme manifestations and treatment
Fever + hemolytic anemiaBabesiosisManual blood-smear review and Babesia PCR help establish the diagnosis. Doxycycline is ineffective against Babesia.
Relapsing febrile episodesB. miyamotoi or soft-tick relapsing feverWestern mountain cabins and some caves are soft-tick exposure clues. Whole-blood PCR is useful even when fever has not relapsed.
Encephalitis or persistent febrile cytopenias despite doxycyclinePowassan or other tick-borne viruses; alternative diagnosis or coinfectionDoxycycline nonresponse is a reason to reassess, not proof of a viral illness.

Ask where and when exposure occurred, including travel, yard work, pets, hunting, animal handling, and overnight stays in rustic cabins. Record illness day, prior antibiotics, immune suppression, splenic function, pregnancy, and transfusion history. Examine all skin and lymph nodes. Initial studies usually include CBC with differential, metabolic panel and hepatic tests; add hemolysis studies, smear/PCR, ECG, lumbar puncture, or tissue sampling according to the syndrome.

Sources [1], [2], [3], [4], [5], [6].

Resident core

Specimens and treatment at the first visit

PresentationEarly evaluationTreatment considerations
Fever with cytopenias / hepatitisCBC/differential, renal and hepatic tests; Ehrlichia/Anaplasma whole-blood PCR, acute IgG serum; blood cultures and additional sepsis testing as indicated.Doxycycline is the preferred empiric therapy when a tick-borne rickettsial illness is suspected. Pretreatment blood improves PCR yield when collection can occur without delaying therapy.
Ulcer or eschar with regional nodesPhotograph and measure the lesion. Discuss lesion swab/biopsy PCR; if tularemia is possible, alert microbiology before cultures and select ulcer material or node aspirate/biopsy. Obtain acute serum for later comparison.Doxycycline covers many eschar-associated rickettsioses. Severe or delayed tularemia requires a different approach below.
Fever with hemolysisCBC, bilirubin, LDH, haptoglobin, manual smear with parasitemia, and Babesia PCR when indicated.Babesia requires a different regimen. Smear or PCR confirmation supports treatment of symptomatic infection. Severe compatible illness warrants urgent smear and PCR, assessment of organ injury, and specialist review of treatment while confirmation is pending.
Meningitis / encephalitisSyndrome-directed blood/CSF testing and standard urgent meningitis/encephalitis evaluation; include travel and immune status.Other indicated empiric meningitis or encephalitis coverage remains necessary during evaluation. See the Lyme neurologic pathway when exposure and findings fit.

CBC, complete blood count; CSF, cerebrospinal fluid; IgG, immunoglobulin G; LDH, lactate dehydrogenase; PCR, polymerase chain reaction.

Sources [5], [11], [13], [14], [4], [15].

Resident core

When to perform LP and what to send

Perform LP when safe for suspected meningitis or encephalitis, including fever with meningismus, persistent unexplained altered mental status, seizures, or focal findings suggesting CNS inflammation. A tick bite or headache alone is not an indication. Assess bleeding risk, clinical stability, and whether neuroimaging is needed before LP. Do not delay empiric treatment while awaiting imaging or CSF.

Obtain opening pressure when appropriate, cell count with differential, protein, glucose with paired blood glucose, Gram stain and bacterial culture. Add HSV/VZV testing and other studies according to the syndrome, host, season, and travel; retain CSF for additional testing. Evaluate common CNS pathogens alongside tick-borne causes. Empiric doxycycline does not replace bacterial meningitis coverage or acyclovir when HSV encephalitis is suspected.

A negative standard 14-target BioFire meningitis/encephalitis panel does not exclude the tick-borne pathogens discussed here; they are not on its menu. Check the actual assay targets.

InfectionTesting or treatment decision
LymeUse serum two-tier testing. If LP is indicated, collect simultaneous CSF/serum for a validated antibody index. CSF PCR is insensitive and not recommended routinely. See Lyme CSF interpretation and sensitivity estimates.
Ehrlichia / Anaplasma / spotted feversCSF inflammation is nonspecific. Continue organism-appropriate blood, tissue, and paired serologic testing. No validated universal CSF PCR sensitivity supports exclusion; a negative result must not determine whether doxycycline is given.
Powassan / TBESerum and/or CSF IgM, with serum neutralization confirmation through public health. Flavivirus cross-reactivity requires interpretation. PCR can confirm selected early or immunocompromised cases, but negative PCR cannot exclude infection; TBE PCR is rarely positive during neurologic illness.
B. miyamotoi / other relapsing-fever BorreliaWhole-blood PCR remains useful. For suspected meningoencephalitis, discuss targeted CSF PCR with microbiology/reference laboratory. Confirm species coverage. CSF sensitivity is not sufficiently established to use a negative result as exclusion.
Heartland / BourbonTesting is primarily serum-based, selected by illness day through public-health coordination. LP is warranted by the neurologic syndrome, not by suspicion of these viruses alone. See specimens and testing access.

Sources [1], [2], [15], [16]; International Encephalitis Consortium diagnostic algorithm; CDC TBE testing; BioFire ME panel targets.

When CNS involvement changes treatment.

CNS, central nervous system; CSF, cerebrospinal fluid; HSV, herpes simplex virus; LP, lumbar puncture; PCR, polymerase chain reaction; TBE, tick-borne encephalitis; VZV, varicella-zoster virus.

Resident core

Bite-site lesions and systemic rashes

Distinguish a localized inoculation lesion from a systemic rash. An eschar is a necrotic crust over an ulcer; not every scab is an infectious eschar. Examine the scalp, axillae, groin, and skin folds. For expanding erythema and bite-reaction mimics, see Lyme rash assessment and photographs.

Eschar relationshipOrganisms / syndromesInterpretation
Common or characteristicR. parkeri, R. rickettsii subsp. californica (364D), R. africae, R. conorii; some other spotted feversAbsence does not exclude them. Multiple eschars after African safari exposure favor African tick-bite fever.
Ulcer that may be necrotic or crustedUlceroglandular tularemiaProminent regional lymphadenopathy is useful. Glandular tularemia has nodes without a visible ulcer.
Usually absentRMSF, ehrlichiosis, anaplasmosis, Lyme, babesiosis, relapsing fever, tick-borne virusesAn eschar lowers the fit for these as the sole explanation, but is not an absolute exclusion.
Important non-tick mimicsAnthrax, ecthyma, bacterial abscess, fungal infection, trauma; scrub typhus and rickettsialpoxScrub typhus is mite-borne; rickettsialpox is also mite-borne. Do not label every necrotic lesion a tick bite or spider bite.

Sources [1], [9], [10], [33].

Resident core

Initial treatment and the exceptions

CDC recommends prompt doxycycline for suspected RMSF, ehrlichiosis, or anaplasmosis, including when an acute test is negative. IV therapy is appropriate in critical illness or when enteral delivery is unreliable.
SituationTreatment considerations
BabesiosisAtovaquone plus azithromycin is preferred for most symptomatic B. microti infections. Parasitemia and organ dysfunction affect treatment and possible exchange transfusion. Other species require a species-specific assessment. See the treatment comparison.
TularemiaCDC includes doxycycline among first-line options for nonsevere, promptly treated tularemia. CDC advises against doxycycline monotherapy in severe disease or when effective treatment has been delayed more than two weeks. See the tularemia section.
Tick-borne virusesTreatment is supportive. The decision about empiric antibacterials depends on whether a treatable bacterial diagnosis remains plausible.
Lyme with neurologic or cardiac diseaseRoute and duration depend on the manifestation. See Lyme treatment pathways.
Pregnancy, child, or doxycycline allergyDoxycycline remains first-line for suspected tick-borne rickettsial disease in children. CDC also recommends it for suspected RMSF in pregnancy. Severe allergy or other pathogens require a separate assessment of effective options.

Treatment options and duration

Sources [6], [12], [18], [19], [21], [22], [23].

General antibiotic selection, coverage and monitoring

Resident core

Tularemia with or without an ulcer

A visible ulcer with regional lymphadenopathy is suggestive, but glandular tularemia may have no ulcer. Ask about animal handling, deer flies, aerosols, and water as well as ticks. Pneumonic and typhoidal disease need not have a skin lesion.

Warn the laboratory before obtaining cultures. Select specimens by the involved site: ulcer material, lymph node aspirate or biopsy, blood, or respiratory material. Discuss PCR availability and transport requirements with microbiology. Early negative serology does not exclude infection; obtain a convalescent specimen.

CDC favors consideration of an initial aminoglycoside in severe disease. Evidence for adding a second active class in severe nonpregnant patients is limited. When effective treatment has been delayed more than two weeks, a bactericidal agent or combination therapy is favored over doxycycline alone. In pregnancy, ciprofloxacin, levofloxacin, or gentamicin are first-line options. For severe disease in pregnancy, CDC prefers gentamicin plus ciprofloxacin or levofloxacin. CDC 2025 recommendations [25]. Treatment options and duration.

Persistent fever or enlarging/fluctuant nodes warrants reassessment for suppuration, inadequate therapy, and another diagnosis. Consider aspiration or drainage when clinically indicated. A slowly resolving node or persistent antibody alone does not establish relapse or justify indefinite antibiotics.

Sources [3], [14], [21], [25].

Resident core

Persistent fever on doxycycline

Question at 48-72 hoursNext step
Has the drug been delivered and absorbed?Missed doses, vomiting, poor enteral access, and interacting supplements or antacids can reduce exposure. IV therapy can address unreliable enteral delivery.
Is a second or different infection present?With hemolysis, test for Babesia. With ulcer/nodes, reassess for tularemia. With cytopenias and little response, consider Heartland/Bourbon alongside other diagnoses.
Is there organ injury or a complication?Reassess respiratory, renal, neurologic, and hemodynamic status. Severe injury can resolve slowly despite appropriate therapy.
Was the initial diagnosis wrong?Revisit non-tick sepsis, viral illness, hematologic disease, and noninfectious causes. A longer doxycycline course is not a diagnostic test.

Clinical improvement is often rapid in uncomplicated ehrlichiosis/anaplasmosis, but this reassessment interval is not an exclusion rule. Do not stop effective treatment solely because fever persists.

Sources [5], [6], [18], [19], [23].

Heartland and Bourbon testing does not require a failed doxycycline course when exposure and cytopenias already meet criteria. See risk factors, testing eligibility, and send-out instructions.

For prolonged unexplained fever after reassessment of the acute illness, see the FUO evaluation.

Resident core

Follow-up, complications, and prevention

For a well patient after an Ixodes bite, use the separate Lyme prophylaxis criteria. The 36-hour threshold is not a safe exclusion rule for all tick-borne infections.

ConditionComplications and follow-up priorities
RMSF / ehrlichiosis / anaplasmosisUntreated disease may cause shock, respiratory failure, kidney injury, encephalitis, or coagulopathy. Severe RMSF can cause ischemic necrosis and permanent deficits. Ehrlichiosis may trigger HLH. Follow organ function and counts; persistent antibodies do not require retreatment.
TularemiaSuppurative nodes, pneumonia, systemic infection, and relapse after inadequate treatment. Persistent enlarging/fluctuant nodes need reassessment for aspiration/drainage and alternative diagnoses, not automatic indefinite antibiotics.
BabesiosisSevere hemolysis, renal/pulmonary compromise, splenic rupture, relapse in immunocompromised hosts. High parasitemia (>10%), severe hemolytic anemia, or severe pulmonary, renal, or hepatic compromise can warrant early discussion of red cell exchange with ID and transfusion medicine. The clinical course informs the decision. See the fellow evidence note.
Powassan / relapsing feverPowassan neuroinvasive disease can cause lasting neurologic deficits or death. Relapsing fever may cause hemodynamic instability, neurologic disease, and pregnancy complications; treatment can precipitate Jarisch-Herxheimer reactions.

HLH, hemophagocytic lymphohistiocytosis; ID, infectious diseases.

Remove ticks promptly with fine-tipped tweezers near the skin; do not burn or smother them. Use EPA-registered repellent and permethrin-treated clothing, inspect skin after exposure, and give return precautions for fever, expanding rash, eschar, dyspnea, syncope, or neurologic symptoms. Do not order Lyme serology or pathogen testing of the tick to decide treatment in an asymptomatic person.

Sources [1], [4], [8], [12], [24], [25].

Resident core

Memory aids

Recall aidWhat to rememberLimit
B. microti: BB gets AA; alternative CQB. microti blood infection: atovaquone + azithromycin; alternatively clindamycin + quinine.AA is preferred for most B. microti infections. Do not automatically apply this preference to B. duncani or divergens-like/MO-1 disease; see the species-specific qualification. Neither regimen is doxycycline.
E/A: two cell lines down, liver enzymes upEhrlichia/Anaplasma commonly cause leukopenia, thrombocytopenia and elevated aminotransferases.Heartland/Bourbon can look the same. Normal early counts do not exclude bacterial infection.
Babesia breaks red cellsHemolysis, anemia, bilirubin/LDH elevation, sometimes parasites on smear.A single negative smear does not exclude low parasitemia; use repeat smear/PCR when indicated.
Eschar plus nodes: sample the skinThink eschar-associated rickettsiosis or ulceroglandular tularemia; lesion PCR can help.Tularemia can be glandular without an ulcer. Warn the lab before culture.
Powassan: think brain; Colorado: fever can come twicePowassan raises concern for neuroinvasive disease; Colorado tick fever is often biphasic.Neither pattern is required or specific. These are recall prompts, not diagnostic criteria.
RMSF: rash may show up laterSuspected RMSF calls for prompt effective treatment before confirmation.Neither an absent rash nor the name Rocky Mountain should exclude RMSF.

These are teaching aids, not validated decision rules. Regimens, durations and contraindications remain in the treatment table. For Lyme, a useful duration sequence is doxycycline 10 days for erythema migrans, 14-21 days for most neurologic/carditis presentations, and 28 days for initial arthritis; drug and manifestation-specific exceptions still apply. Lyme regimens.

Sources [22], [1], [12].

Resident core

Cases for discussion

Missouri, day 4 of fever, platelets 65,000, leukopenia, AST elevation, no rash, negative Ehrlichia antibody. Wait?

The day-4 antibody result does not exclude ehrlichiosis. Doxycycline is time-sensitive in this presentation. Whole-blood PCR is useful before treatment when collection can occur without delay, and convalescent serology can help confirm the diagnosis.

Ozark exposure, inoculation ulcer, bulky nodes, three weeks of illness. Five days of doxycycline for a presumed tick infection did not resolve it.

The ulcer and bulky nodes favor tularemia. The laboratory needs advance warning before culture. Lesion or node sampling and serology can support diagnosis. After this delay, CDC favors a bactericidal agent or combination therapy over doxycycline alone. Suppuration may require drainage.

Nantucket exposure, treated erythema migrans, fever persists on doxycycline with falling hemoglobin and rising bilirubin.

The hemolysis suggests babesiosis. Smear and PCR help establish infection, while parasitemia and organ injury determine urgency. In severe compatible illness, assessment for Babesia treatment is urgent while testing is pending.

Fellow detail / Reference

Species, vectors, regions, and distinguishing findings

Infection / organismVector and exposure geographyTypical clues and skin findings
Ehrlichiosis
E. chaffeensis, E. ewingii
Lone star tick, Amblyomma americanum; south-central, southeastern, and eastern U.S., including MissouriUsually 5-14 days after exposure. Fever, headache, GI symptoms, cytopenias, hepatitis. Rash is less frequent in adults; no characteristic eschar. E. chaffeensis infects monocytes; E. ewingii granulocytes.
E. muris eauclairensisIxodes scapularis; especially Minnesota/WisconsinFebrile illness resembling anaplasmosis; no characteristic eschar.
Anaplasmosis
A. phagocytophilum
I. scapularis in Northeast/upper Midwest; I. pacificus in WestUsually 5-14 days. Granulocyte infection; leukopenia, thrombocytopenia, hepatitis. Rash uncommon; consider coinfection if prominent. No typical eschar.
RMSF
R. rickettsii
Dermacentor variabilis, D. andersoni; brown dog ticks in some southwestern/Mexican settings. Important in south-central/southeastern U.S., not limited to the RockiesUsually 3-12 days. Fever precedes rash, which can progress from macules to petechiae and involve palms/soles. Usually no eschar.
R. parkeri rickettsiosisA. maculatum group ticks; chiefly southeastern/Atlantic associations, but also human disease in Arizona. Infected ticks have been detected in New Mexico. Vector detections do not alone prove local human disease.Eschar often precedes fever; regional nodes and maculopapular or vesicular rash. Usually milder than RMSF.
Pacific Coast tick fever
R. rickettsii subsp. californica (364D; formerly called R. philipii)
Pacific Coast tick, D. occidentalis; human disease described chiefly in California, with vector range extending along the Pacific CoastEschar and regional lymphadenopathy; generalized rash often absent.
Tularemia
Francisella tularensis
Dermacentor and lone star ticks; deer flies, rabbits/rodents, animal tissue, aerosols, or contaminated water. Central U.S. is important, including Missouri, Arkansas, Oklahoma, KansasOften 3-5 days, range 1-21. Painful regional nodes with an inoculation ulcer, sometimes necrotic/crusted; ulcer may be absent. Pneumonic, typhoidal, ocular, and oropharyngeal forms also occur.
Babesiosis
B. microti; less often B. duncani or divergens-like organisms
B. microti primarily Northeast/upper Midwest, with additional transmission in neighboring states. B. duncani has been reported in California/Washington; divergens-like/MO-1 disease in Missouri and other states. Transfusion-associated disease is not confined to tick exposure regions.Often weeks to months after exposure. Fever, hemolysis, thrombocytopenia; no characteristic rash or eschar. Severe disease with asplenia, advanced age, or immune suppression.
Hard-tick relapsing fever
B. miyamotoi
Ixodes; overlaps Lyme exposure regionsFever, chills, headache, cytopenias; rash uncommon. Meningoencephalitis in immunocompromised hosts.
Soft-tick relapsing fever
B. hermsii, B. turicatae and others
Ornithodoros; western mountain cabins (B. hermsii) and parts of Texas, including caves (B. turicatae). Similar illnesses occur internationally; the U.S. list is not a global range.Abrupt recurring fevers; brief nocturnal bites often unnoticed. No typical eschar.

CBC, complete blood count; ECG, electrocardiogram; GI, gastrointestinal; PCR, polymerase chain reaction; RMSF, Rocky Mountain spotted fever.

Sources [1], [2], [3], [4], [7], [8], [9], [33].

Geographic exceptions: Babesia species; soft-tick relapsing fever; southwestern R. parkeri. Geographic review October 31, 2026.

Fellow detail / Reference

Diagnostic tests and timing

For Lyme serology, including stage-specific sensitivity and cross-reactivity, see the Lyme testing section.

Suspected infectionUseful test / timingLimitations and cross-reactivity
Ehrlichia / AnaplasmaEDTA whole-blood PCR during first week, ideally before doxycycline; paired IgG IFA, acute and 2-10 weeks laterPCR sensitivity falls after treatment, often within 48 hours. Negative PCR does not exclude. A fourfold IgG rise supports recent infection. Cross-reactions occur between genera and species; IgM is unreliable.
Spotted fever rickettsiosisPaired IgG IFA, acute and 2-10 weeks later; lesion swab or biopsy PCR when an eschar is present; rash biopsy PCR/IHC where availableBlood PCR is relatively insensitive in RMSF, especially early. SFG antibodies often cannot distinguish R. rickettsii from other species. One positive "RMSF" titer is not species confirmation or proof of active disease.
TularemiaAlert lab before cultures. Send ulcer material, node aspirate/biopsy, blood, or respiratory specimen as clinically appropriate; PCR through capable labs; paired serologyAntibodies often appear only after 2-3 weeks. Obtain acute serum and repeat 2-3 weeks later. Cross-reactions include Brucella. Culture poses a laboratory-acquisition risk; do not submit without warning.
BabesiaManual thin smear with parasitemia percentage; PCR if smear negative or species confirmation neededRepeat smear/PCR when suspicion remains high. A B. microti-only assay can miss other species. Antibody alone does not establish current infection; does not reliably measure clearance.
Relapsing feverWhole-blood PCR, preferably during fever before therapy; smear particularly useful for soft-tick diseaseConfirm assay coverage of B. miyamotoi versus soft-tick species. Serology becomes more useful after about 14 days; some assays cannot distinguish relapsing-fever species and may produce misleading Lyme reactivity.
PowassanSerum/CSF IgM with serum neutralization confirmation; molecular testing in selected early or immunocompromised casesFlavivirus antibody cross-reactivity complicates interpretation; contact public health. Negative PCR does not exclude.
Heartland / BourbonCoordinate with public health: serum RT-PCR plus antibody testing before day 14; antibody testing from day 14 onward, with later PCR considered in immunocompromised patients. Heartland tests include IgM and neutralization; Bourbon has no specific IgM assay, so serologic diagnosis needs paired samples.Routine commercial tick panels often omit these. Use the laboratory's specimen and timing requirements; do not assume CDC testing is available without checking.

CSF, cerebrospinal fluid; EDTA, ethylenediaminetetraacetic acid; EIA, enzyme immunoassay; EBV, Epstein-Barr virus; FDA, Food and Drug Administration; IFA, indirect fluorescent antibody; IgG/IgM, immunoglobulin G/M; IHC, immunohistochemistry; SFG, spotted fever group.

Sources [4], [5], [7], [8], [11], [13], [14], [15], [16], [17].

Fellow detail / Reference

When doxycycline is sufficient, and when it is not

Route depends on illness severity and the reliability of enteral delivery. Several alternatives require renal adjustment. Doxycycline generally does not, but iron, calcium supplements, and antacids can impair absorption. Water and upright posture reduce pill esophagitis. Fluoroquinolone tendon, neurologic, QT, and aortic risks and gentamicin renal and ototoxicity risks affect drug selection.

SyndromeAgents and treatment durationSelection and exceptions
RMSF or other spotted feverDoxycycline. For RMSF, CDC describes a minimum course of 5-7 days and at least 3 days after fever resolves, with clinical improvement.Doxycycline is preferred, including in children. Beta-lactams do not substitute. Severe allergy requires specialist management, sometimes desensitization. Chloramphenicol has worse observed outcomes and does not cover ehrlichiosis/anaplasmosis; it is not a routine substitute.
EhrlichiosisDoxycycline for at least 5-7 days and until afebrile for 72 hours with clinical improvement.No equally reliable routine substitute. Complicated disease may require a longer course.
AnaplasmosisDoxycycline for 10-14 days.CDC uses this duration to account for possible concurrent early Lyme disease. Disseminated Lyme manifestations have separate treatment requirements. Rifampin is a limited-evidence option for selected mild anaplasmosis, including in pregnancy, only when the clinical assessment excludes RMSF and possible Lyme coinfection has been addressed. A negative early test alone does not exclude RMSF. CDC describes 7-10 days of rifampin in small pediatric series.
Tularemia, nonsevere and promptly treatedCDC first-line options include ciprofloxacin, levofloxacin, or gentamicin for 10 days, or doxycycline for 14-21 days in selected patients.Fluoroquinolones have a shorter usual course than doxycycline. Adverse effects and interactions affect selection. Doxycycline monotherapy is unsuitable in severe disease or after a delay of more than two weeks.
Tularemia, severeAn initial parenteral aminoglycoside such as gentamicin is a CDC option for severe illness. The usual gentamicin course is 10 days, with dosing individualized by renal function and drug levels.Renal function and drug levels guide the interval. Evidence for routine combination therapy in severe nonpregnant patients is limited. Persistent fever, abscess, or other complicated disease may warrant longer treatment or source control. See the neuroinvasive combination regimen and duration.
B. microti babesiosis, symptomatic, immunocompetentOral atovaquone plus azithromycin for 7-10 days for most immunocompetent patients. Dietary fat improves atovaquone absorption.Doxycycline is ineffective. In severe hospitalized B. microti infection, IDSA favors IV azithromycin plus oral atovaquone initially.
B. microti babesiosis, alternative regimenClindamycin plus quinine for 7-10 days in most immunocompetent patients. In severe illness, IV clindamycin plus oral quinine is an alternative when preferred therapy is ineffective or unsuitable.This combination is less well tolerated. CDC generally favors clindamycin plus quinine for symptomatic babesiosis during pregnancy, with specialist assessment of the individual situation.
Hard-tick relapsing feverA two-week oral course of doxycycline or amoxicillin was effective in published case series of most patients.Severe illness/meningoencephalitis favors initial IV ceftriaxone. Evidence is from case series, not randomized treatment trials.
Soft-tick relapsing feverDoxycycline for 10 days is the preferred CDC regimen in patients without pregnancy or neurologic complications.Pregnancy or neurologic disease favors an initial parenteral beta-lactam such as ceftriaxone, with 10-14 days total treatment. The first 4 hours require observation for a Jarisch-Herxheimer reaction.
Powassan, Heartland, Bourbon, Colorado tick feverSupportive care; no established pathogen-specific antiviral treatmentAntibacterials address only a possible bacterial infection. Reassessment of competing diagnoses informs their duration.

These preferred-regimen data primarily concern B. microti. Suspected or confirmed B. duncani or B. divergens/divergens-like infection calls for species confirmation and specialist input because B. microti treatment evidence may not apply. Published experience commonly uses IV clindamycin plus oral quinine; comparative evidence is sparse. Severe disease calls for prompt assessment of exchange-transfusion needs. MO-1 is not automatically equivalent to European B. divergens. IDSA species-specific treatment evidence [4].

In the 2026 STOP-BABESIOSIS study of 629 hospitalized adults with severe babesiosis, red cell exchange was associated with a lower combined rate of in-hospital death or 30-day readmission (3.6% vs 9.8%, adjusted OR 0.22, 95% CI 0.09-0.51). Residual confounding is possible. The study supports early multidisciplinary consideration in severe illness. It did not establish a parasitemia cutoff that predicts benefit. STOP-BABESIOSIS study.

For tularemia in pregnancy, CDC recommends ciprofloxacin, levofloxacin, or gentamicin as first-line treatment, using the usual adult durations. For severe disease, CDC prefers gentamicin plus ciprofloxacin or levofloxacin. Selection depends on severity, organ function, and pregnancy-specific risks. CDC 2025 recommendations [25].

IV, intravenous.

CDC recommends prompt doxycycline for children with suspected RMSF, ehrlichiosis, or anaplasmosis. Short courses have not been shown to stain permanent teeth. Suspected RMSF during pregnancy also warrants prompt doxycycline while maternal and fetal risks are discussed. Rifampin does not treat RMSF or Lyme coinfection. Sulfonamides can worsen RMSF and should not be used to treat it.

Sources [6], [7], [8], [18], [19], [20], [21], [22], [23].

Fellow detail / Reference

Treatment with CNS involvement

The pathogen, neurologic manifestation, severity, and reliability of absorption determine the treatment route. Abnormal CSF alone does not distinguish these pathways.

InfectionTesting or treatment decision
Lyme meningitis / radiculoneuritisOral doxycycline or an IV option such as ceftriaxone are supported for 14-21 days. The route depends on tolerability, severity, and whether other CNS infections have been addressed. Parenchymal brain or spinal cord disease calls for IV treatment. See Lyme neurologic treatment.
RMSF / ehrlichiosis; suspected anaplasmosisDoxycycline remains first-line. IV therapy is appropriate for critical illness, obtundation, vomiting, or unreliable absorption. Ceftriaxone does not replace doxycycline for these infections. Duration depends on the organism and clinical recovery, with longer courses sometimes needed for severe or complicated disease. CNS disease is unusual in anaplasmosis and warrants a search for coinfection or another cause.
Neuroinvasive tularemiaCDC recommends gentamicin plus ciprofloxacin or levofloxacin. Successful case reports included at least 10 days of aminoglycoside treatment. CDC describes 21 days of total therapy when gentamicin is stopped and treatment transitions to an active oral agent. Gentamicin plus doxycycline is an alternative when a fluoroquinolone is unsuitable. Evidence is limited to rare cases. Renal function and drug levels guide gentamicin use. Routine ceftriaxone meningitis therapy does not cover tularemia.
Soft-tick relapsing fever with neurologic diseaseCDC advises an initial parenteral beta-lactam such as ceftriaxone, with 10-14 days total treatment. The first 4 hours require observation for a Jarisch-Herxheimer reaction.
B. miyamotoi meningoencephalitisCDC lists IV ceftriaxone as an initial option in severe disease, including meningoencephalitis. CNS-specific duration remains uncertain and requires individualized specialist assessment. The two-week oral course applies to uncomplicated illness.
Powassan / TBE and other tick-borne viral diseaseSupportive care. Neuroinvasive disease requires monitoring for seizures, raised intracranial pressure, and loss of airway protection. No established specific antiviral for Powassan or TBE. Empiric acyclovir addresses possible HSV. Its duration depends on the evaluation for HSV encephalitis.

Sources [1], [7], [8], [25]; CDC neurologic Lyme regimens; CDC Powassan treatment; CDC TBE treatment.

Fellow detail / Reference

Tick-borne viruses and send-out testing

Doxycycline does not treat these viruses, but suspected viral disease does not justify delaying treatment for plausible RMSF/ehrlichiosis or other urgent bacterial disease. Supportive care includes monitoring for shock, respiratory failure, encephalitis, and other organ injury. There is no established pathogen-specific antiviral therapy for these four U.S. infections.

VirusExposure / riskWhen to consider itTesting
HeartlandLone star tick exposure in eastern, southeastern or south-central U.S., including Missouri; often warm-season outdoor exposure. Immunocompromise and multiple comorbidities have been associated with severe or fatal illness.Ehrlichiosis-like fever, leukopenia, thrombocytopenia, GI symptoms and transaminase elevation. Persistent illness despite doxycycline is a clue; HLH or multiorgan failure can occur.Acute serum RT-PCR and serology through public health. The reference-laboratory example uses serum RNA PCR. A negative result, especially later in illness, does not exclude infection.
BourbonRare recognized U.S. infections, associated with tick exposure. Geographic limits and predictors of severity are not well established; do not restrict testing to Kansas.Fever, fatigue, GI symptoms, leukopenia/thrombocytopenia, sometimes maculopapular rash. Severe and fatal cases reported; findings overlap with ehrlichiosis and Heartland.Public-health RT-PCR and neutralization testing. No specific IgM assay; paired sera are needed for serologic evidence of acute infection.
PowassanEspecially Northeast/Great Lakes Ixodes exposure. Older adults, children and immunocompromised people have greater risk of neuroinvasive disease.Consider with meningitis/encephalitis or compatible acute febrile illness after exposure. Incubation 1-5 weeks. About 10% of neuroinvasive cases are fatal; about half of survivors have neurologic sequelae.Serum/CSF IgM, with serum neutralization confirmation through state/public-health laboratories. Consider molecular testing early or with immunocompromise; negative PCR does not exclude.
Colorado tick feverWestern U.S. and western Canadian mountain habitat, typically 4,000-10,000 feet; D. andersoni exposure. The 2013-2022 U.S. series identified likely acquisition in Montana, Wyoming, Oregon, Colorado, Utah and Idaho; not an exhaustive range.Often biphasic fever with leukopenia and thrombocytopenia. Usually self-limited; rare severe neurologic disease, particularly in children.Serum RT-PCR is most useful early. Antibody response may be delayed 14-21 days. Coordinate commercial/reference or public-health testing. Avoid blood/bone-marrow donation for six months after infection.

Sources [36], [27], [24], [15], [28], [41].

Heartland and Bourbon testing eligibility

CDC guidance uses acute febrile illness within the past three months, plus at least one exposure criterion and one clinical criterion. Exposure criteria are tick exposure in the three weeks before onset during spring through fall, or residence/travel in an area with previous virus evidence. Clinical criteria are unexplained WBC <4,500/microliter or platelets <150,000/microliter, or lack of response to appropriate treatment for suspected tick-borne disease. Treatment failure is not required when exposure and cytopenias already fit.

Before day 14, send serum for RT-PCR and antibody testing. From day 14 onward, prioritize antibody testing; later RT-PCR may still be useful in immunocompromised patients. Arrange a convalescent sample when required. CDC guidance does not accept specimens collected more than three months after symptom onset for this pathway.

Sources [16].

Where to send specimens

Contact hospital microbiology and the state/local health department before shipping. They should confirm current assay availability, specimen type/volume, storage, paired-sample timing, and the receiving laboratory. For CDC referrals, submit through the health department with the CDC 50.34 form, onset and collection dates, immune status, exposure location, and travel history. CDC pages currently caution that some assays may be unavailable; a published test menu is not a guarantee of acceptance.

In Missouri, contact DHSS communicable disease staff at 573-751-6113 during business hours. After hours and on weekends, the DHSS reporting number is 800-392-0272. The state manual listed both numbers on November 9, 2026. Local collection and send-out workflows vary.

Mayo Clinic Laboratories HRTVS is one example of a reference-laboratory Heartland serum PCR. The catalog entry checked November 9, 2026 specifies 0.5 mL serum, centrifuged and aliquoted into a sterile container within two hours. Mayo cautions that molecular testing may be negative after more than one week of symptoms. The test targets Heartland virus RNA. Paired serology can still be needed, and Bourbon testing requires a separate public health pathway. Local microbiology can confirm assay availability, handling, and routing.

Sources [42], [26].

Imported viral infections

InfectionExposure / presentationTesting and immediate action
TBEFocal European/Asian forest exposure; occasionally unpasteurized dairy. Febrile illness may progress to meningitis/encephalitis.Consult public health for serum/CSF antibody testing and interpretation of flavivirus cross-reactivity. Supportive care; pretravel vaccination is available for appropriate risk itineraries.
CCHFRelevant travel plus tick, livestock/slaughter, or infected blood/body-fluid exposure. Early fever, myalgias, or gastrointestinal symptoms can precede bleeding and organ failure.When the exposure and illness suggest CCHF, isolate immediately and notify infection prevention and public health. Coordinate PPE and safe specimen handling with infection prevention and the laboratory. Prompt evaluation and care for other likely causes can proceed with appropriate precautions. CDC screening and isolation guidance. CDC laboratory guidance.
SFTSEast and Southeast Asian exposure, including rural/outdoor activity or infected animal/body-fluid contact; fever, GI symptoms and cytopenias. Use the world map evidence categories rather than limiting consideration to China/Japan/Korea.Consult public health for reference-laboratory RT-PCR on acute specimens; paired serology may assist. Alert infection prevention because blood/body-fluid transmission is documented. Treatment requires specialist and destination-specific guidance.

Sources [29], [39], [40].

CSF, cerebrospinal fluid; DHSS, Department of Health and Senior Services; HLH, hemophagocytic lymphohistiocytosis; IgM, immunoglobulin M; PPE, personal protective equipment; RT-PCR, reverse-transcription polymerase chain reaction; WBC, white blood cell count.

Fellow detail / Reference

Diagnostic performance and difficult interpretations

Test / questionEvidence and interpretation
Rickettsial PCR / IFA performanceNo universal sensitivity applies across organism, specimen, illness day, and antibiotic exposure. Tissue or eschar PCR may outperform blood for spotted fevers; whole blood is preferred for Ehrlichia/Anaplasma. An analytically specific PCR still has limited clinical sensitivity if the organism is absent from that specimen. A fourfold rise in paired spotted-fever IgG supports recent infection but usually does not identify the species.
Broad tick panelsRead targets and specimen requirements. A negative panel does not exclude pathogens not included, early antibody-negative disease, or infection suppressed by antibiotics. Multiple positive serologies may represent cross-reactivity rather than multiple active infections.

Order add-on testing through microbiology rather than assuming all PCR panels are interchangeable. The send-out testing section has a reference-laboratory Heartland serum RNA assay example and specimen guidance. For unusual viruses, coordinate testing and current availability with the state health department.

Sources [1], [5], [11], [13], [15], [16], [17], [26].

Fellow detail / Reference

Coinfection, immune suppression, travel, and mimics

Shared Ixodes exposure can produce more than one infection. See coinfection in the Lyme presentation.

SituationClinical consequence
Ixodes exposure with Lyme plus persistent fever/cytopeniasAnaplasma and Babesia are possible coinfections. Doxycycline covers Anaplasma. Confirmed symptomatic babesiosis warrants a separate regimen. Severe illness with high suspicion calls for urgent assessment while testing is pending. Hemolysis favors Babesia.
Highly immunocompromised babesiosis, particularly B-cell depletionTreatment commonly requires at least six weeks, including two final weeks with negative blood smears. Monitor smears through clearance; persistent symptoms despite negative smears may justify PCR. Immunocompetent recovered patients do not need serial PCR to prove cure.
Asymptomatic Babesia detectionUsually no treatment; parasites persisting on thin blood smear for more than one month warrant treatment. Do not treat an isolated antibody alone. Individualize high-risk hosts.
Heartland or Bourbon virusCentral/southern/eastern U.S.; fever, leukopenia, thrombocytopenia, sometimes severe multiorgan disease. Consider after apparent ehrlichiosis fails to respond, while checking alternative diagnoses and coinfections.
Powassan virusIxodes-associated exposure especially Northeast/Great Lakes; meningitis/encephalitis. Antibody confirmation requires attention to other flavivirus exposure/vaccination.
Colorado tick feverWestern mountainous U.S.; D. andersoni; biphasic fever, leukopenia, thrombocytopenia. Early RT-PCR is useful; later serology may be needed. Supportive care.
African tick-bite fever, R. africaeSub-Saharan Africa/Caribbean exposure; multiple eschars, regional nodes, clustered illness among travelers. Doxycycline is used.
Mediterranean spotted fever, R. conorii; other imported spotted feversMediterranean/Africa and other regional exposures; fever, rash, often eschar. Some are severe. Doxycycline remains first-line; do not infer a benign course solely from an eschar.
Tick-borne encephalitis / Crimean-Congo hemorrhagic feverTravel to endemic regions of Europe/Asia for TBE; parts of Africa/Asia/Europe for CCHF. Encephalitis warrants urgent evaluation for TBE when the exposure fits. Compatible acute illness after a credible CCHF exposure warrants immediate isolation and notification of infection prevention and public health.
Tick paralysis / alpha-gal syndromeNoninfectious tick-associated conditions. Ascending weakness requires a thorough search for an attached tick and removal; alpha-gal causes delayed allergic reactions after mammalian products. Neither is treated with antibiotics.

CCHF, Crimean-Congo hemorrhagic fever; RT-PCR, reverse-transcription PCR; STARI, southern tick-associated rash illness; TBE, tick-borne encephalitis.

Sources [3], [4], [10], [12], [15], [16], [22], [23], [24], [27], [28], [29], [30], [31], [32].

Reference

Sources and related lectures

Image credits appear with each figure. The sources below provide clinical guidance, primary studies, and specimen requirements.

  1. CDC tick-borne rickettsial guideline, 2016
  2. CDC Tickborne Diseases of the United States, reference manual
  3. CDC tularemia clinical findings
  4. IDSA babesiosis guideline, 2020
  5. CDC ehrlichiosis diagnosis
  6. CDC anaplasmosis clinical care
  7. CDC hard-tick relapsing fever guidance, July 2026
  8. CDC soft-tick relapsing fever guidance, July 2026
  9. CDC other spotted-fever clinical findings
  10. CDC Yellow Book 2026, rickettsial diseases
  11. CDC anaplasmosis testing
  12. AAN/ACR/IDSA Lyme guideline, 2020
  13. CDC RMSF diagnosis
  14. CDC tularemia diagnosis
  15. CDC Powassan diagnosis, October 2026
  16. CDC Heartland/Bourbon testing guidance
  17. Myers et al. Eschar-swab diagnosis, EID 2013
  18. CDC RMSF clinical care
  19. CDC ehrlichiosis clinical care
  20. CDC erythema migrans treatment, March 2026
  21. CDC tularemia clinical care, January 2026
  22. CDC babesiosis clinical care
  23. CDC Heartland treatment
  24. CDC Powassan clinical findings
  25. CDC tularemia antimicrobial recommendations, 2025
  26. Mayo Clinic Laboratories HRTVS
  27. CDC Bourbon clinical guidance
  28. CDC Colorado tick fever diagnosis
  29. CDC Yellow Book, tick-borne encephalitis
  30. CDC alpha-gal syndrome
  31. CDC DPDx ticks and tick paralysis
  32. CDC viral hemorrhagic fever infection prevention
  33. Rickettsia rickettsii subsp. californica: formal nomenclature of the Pacific Coast tick fever agent
  34. CDC tick-borne disease reference manual
  35. CDC tick distributions and limitations
  36. CDC Heartland clinical features
  37. CDC Yellow Book rickettsial diseases
  38. CDC TBE destination-specific risk
  39. WHO CCHF fact sheet
  40. Japan national SFTS risk assessment
  41. CDC Colorado tick fever transmission
  42. Missouri communicable disease reporting contacts
  43. CDC screening and isolation for suspected viral hemorrhagic fever
  44. STOP-BABESIOSIS Investigators. Red Blood Cell Exchange Transfusion for Severe Babesiosis. JAMA Internal Medicine, 2026

Related modules: Antibiotic selection and toxicity; lecture catalog.